Modernizing Drug Development | Vital Science Podcast: S4, E10

The recent passage of the FDA Modernization Act 2.0 has put the onus on researchers to explore alternatives to in vivo testing for drug compounds, but what does this mean for the future of biosimilar development? Find out from Michael Templin from Charles River’s Scientific Advisory Services team on the season finale of Vital Science.
bit.ly/44eqxy3
You can subscribe to Vital Science and Sounds of Science on Apple Podcasts, Spotify, Stitcher, or wherever you get your podcasts.
Apple Podcast: podcasts.apple.com/us/podcast...
Spotify: open.spotify.com/show/58GDJy5...
RSS: feeds.transistor.fm/vital-sci...